Found: 21
Select item for more details and to access through your institution.
Daratumumab in transplant-eligible patients with newly diagnosed multiple myeloma: final analysis of clinically relevant subgroups in GRIFFIN.
- Published in:
- Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-024-01088-6
- By:
- Publication type:
- Article
Lenalidomide‐based response‐adapted therapy for older adults without high risk myeloma.
- Published in:
- British Journal of Haematology, 2019, v. 184, n. 5, p. 735, doi. 10.1111/bjh.15700
- By:
- Publication type:
- Article
Recurrent cardiotoxicity potentiated by the interaction of proteasome inhibitor and immunomodulatory therapy for the treatment of multiple myeloma.
- Published in:
- British Journal of Haematology, 2018, v. 180, n. 2, p. 271, doi. 10.1111/bjh.14970
- By:
- Publication type:
- Article
Health‐related quality of life in transplant‐eligible patients with newly diagnosed multiple myeloma treated with daratumumab, lenalidomide, bortezomib, and dexamethasone: Patient‐reported outcomes from GRIFFIN.
- Published in:
- American Journal of Hematology, 2024, v. 99, n. 7, p. 1257, doi. 10.1002/ajh.27326
- By:
- Publication type:
- Article
CancerCellTracker: a brightfield time-lapse microscopy framework for cancer drug sensitivity estimation.
- Published in:
- Bioinformatics, 2022, v. 38, n. 16, p. 4002, doi. 10.1093/bioinformatics/btac417
- By:
- Publication type:
- Article
The bone ecosystem facilitates multiple myeloma relapse and the evolution of heterogeneous drug resistant disease.
- Published in:
- Nature Communications, 2024, v. 15, n. 1, p. 1, doi. 10.1038/s41467-024-46594-0
- By:
- Publication type:
- Article
Constitutive RelB activation in v-Src-transformed fibroblasts: Requirement for IκB degradation.
- Published in:
- Journal of Cellular Biochemistry, 1999, v. 73, n. 2, p. 237, doi. 10.1002/(SICI)1097-4644(19990501)73:2<237::AID-JCB10>3.0.CO;2-H
- By:
- Publication type:
- Article
Replicative Instability Drives Cancer Progression.
- Published in:
- Biomolecules (2218-273X), 2022, v. 12, n. 11, p. 1570, doi. 10.3390/biom12111570
- By:
- Publication type:
- Article
Patient-Reported Outcomes among Multiple Myeloma Patients Treated with Standard of Care Idecabtagene Vicleucel.
- Published in:
- Cancers, 2023, v. 15, n. 19, p. 4711, doi. 10.3390/cancers15194711
- By:
- Publication type:
- Article
Therapeutic Targeting of Protein Disulfide Isomerase PDIA1 in Multiple Myeloma.
- Published in:
- Cancers, 2021, v. 13, n. 11, p. 2649, doi. 10.3390/cancers13112649
- By:
- Publication type:
- Article
Subsequent primary malignancies and acute myelogenous leukemia transformation among myelodysplastic syndrome patients treated with or without lenalidomide.
- Published in:
- Cancer Medicine, 2016, v. 5, n. 7, p. 1694, doi. 10.1002/cam4.721
- By:
- Publication type:
- Article
Clinical Outcomes of Patients With Plasma Cell Leukemia in the Era of Novel Therapies and Hematopoietic Stem Cell Transplantation Strategies: A Single-Institution Experience.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2011, v. 11, n. 6, p. 507, doi. 10.1016/j.clml.2011.06.010
- By:
- Publication type:
- Article
PLK1 stabilizes a MYC-dependent kinase network in aggressive B cell lymphomas.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Daratumumab + Lenalidomide, Bortezomib & Dexamethasone Improves Depth of Response in Transplant-eligible Newly Diagnosed Multiple Myeloma: GRIFFIN.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e353, doi. 10.1016/j.clml.2019.09.583
- By:
- Publication type:
- Article
Oprozomib in patients with newly diagnosed multiple myeloma.
- Published in:
- Blood Cancer Journal, 2019, v. 9, n. 9, p. N.PAG, doi. 10.1038/s41408-019-0232-6
- By:
- Publication type:
- Article
Phase II study of pegylated liposomal doxorubicin, low-dose dexamethasone, and lenalidomide in patients with newly diagnosed multiple myeloma.
- Published in:
- American Journal of Hematology, 2014, v. 89, n. 1, p. 62, doi. 10.1002/ajh.23587
- By:
- Publication type:
- Article
Treatment of acquired drug resistance in multiple myeloma by combination therapy with XPO1 and topoisomerase II inhibitors.
- Published in:
- Journal of Hematology & Oncology, 2016, v. 9, p. 1, doi. 10.1186/s13045-016-0304-z
- By:
- Publication type:
- Article
Metabolomic signatures of carfilzomib‐related cardiotoxicity in patients with multiple myeloma.
- Published in:
- CTS: Clinical & Translational Science, 2024, v. 17, n. 5, p. 1, doi. 10.1111/cts.13828
- By:
- Publication type:
- Article
A comparison of salvage infusional chemotherapy regimens for recurrent/refractory multiple myeloma.
- Published in:
- 2015
- By:
- Publication type:
- journal article
Assessment of Clonotypic Rearrangements and Minimal Residual Disease in Lymphoid Malignancies: A Large Cancer Center Experience Using clonoSEQ.
- Published in:
- Archives of Pathology & Laboratory Medicine, 2022, v. 146, n. 4, p. 485, doi. 10.5858/arpa.2020-0457-OA
- By:
- Publication type:
- Article
Leukoencephalopathy During Daratumumab-Based Therapy: A Case Series of Two Patients with Multiple Myeloma.
- Published in:
- 2022
- By:
- Publication type:
- Case Study